Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells

We have evaluated the antitumor effects of gefitinib (Iressa, ZD1839) in SNU-1 human gastric cancer cells (hMLH1-deficient and epidermal growth factor receptor-overexpressed) when given alone or as a doublet with oxaliplatin (LOHP), 5-fluorouracil (5-FU) or paclitaxel (PTX). The four drugs showed IC50s ranging from 1.81 nM to 13.2 μM. LOHP and PTX induced G2/M arrest, 5-FU increased S phase, and gefitinib increased G1 in a concentration-dependent manner. The analysis using the previously developed cytostatic TPi model showed that 64 and 80% of the overall growth inhibition was attributed to cell cycle arrest in cells exposed to 7.55 μM of LOHP or 10 nM of PTX for 72 h, respectively. PTX+gefitinib showed greatest synergism as determined by combination index analysis and apoptosis induced by PTX was potentiated by the co-administration of gefitinib. LOHP+gefitinib showed a similar, although to a lesser degree, synergistic effect. This study demonstrates the antitumor activity and the significant cell cycle arrest induced by gefitinib in SNU-1 human gastric carcinoma cells, and its synergistic interaction with LOHP and PTX.

[1]  K. Shin,et al.  Absence or decreased levels of the hMLH1 protein in human gastric carcinoma cell lines: implication of hMLH1 in alkylation tolerance , 1998, Journal of Cancer Research and Clinical Oncology.

[2]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  G Milano,et al.  Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) , 2002, British Journal of Cancer.

[4]  C. Bokemeyer,et al.  Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer , 2002, Anti-cancer drugs.

[5]  G. Zupi,et al.  ZD1839 (IRESSA), an EGFR‐selective tyrosine kinase inhibitor, enhances taxane activity in bcl‐2 overexpressing, multidrug‐resistant MCF‐7 ADR human breast cancer cells , 2002, International journal of cancer.

[6]  A. Simpson,et al.  Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric carcinomas with high‐level microsatellite instability , 2000, International journal of cancer.

[7]  Vittorio Ricci,et al.  Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. Perez-soler.  HER1/EGFR targeting: refining the strategy. , 2004, The oncologist.

[9]  Y.‐H. Kang,et al.  Comprehensive analysis of promoter methylation and altered expression of hMLH1 in gastric cancer cell lines with microsatellite instability , 2002, Journal of Cancer Research and Clinical Oncology.

[10]  S. Aebi,et al.  The role of DNA mismatch repair in drug resistance. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Fontanini,et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  A. Paradiso,et al.  The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines , 2003, Cancer Chemotherapy and Pharmacology.

[13]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[14]  K. Shirouzu,et al.  Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma. , 2001, The Kurume medical journal.

[15]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[16]  A. Harłozińska,et al.  Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. , 1998, Anticancer Research.

[17]  G Milano,et al.  Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer , 2002, British Journal of Cancer.

[18]  J. Minna,et al.  Chemosensitivity testing of human lung cancer cell lines using the MTT assay. , 1988, British Journal of Cancer.

[19]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Y. Mok,et al.  Paclitaxel, 5‐fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma , 1999, Cancer.

[21]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[22]  J. Nährig,et al.  Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system , 2004, Modern Pathology.

[23]  A. Paradiso,et al.  Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. , 2003, Biochemical pharmacology.

[24]  J. Usuda,et al.  A Computational Model for Quantitative Analysis of Cell Cycle Arrest and Its Contribution to Overall Growth Inhibition by Anticancer Agents , 2000, Japanese journal of cancer research : Gann.

[25]  J. Mendelsohn,et al.  Epidermal growth factor receptor family and chemosensitization. , 1997, Journal of the National Cancer Institute.

[26]  M. Ruge,et al.  Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[27]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.